Published in Eur J Pharm Sci on March 25, 2010
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol (2011) 0.81
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood (2010) 2.38
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol (2010) 1.17
Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release. AAPS PharmSci (2003) 1.15
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol (2009) 1.00
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res (2006) 0.97
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2005) 0.88
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2005) 0.86
A novel HPLC assay for pentamidine: comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney. J Pharm Pharm Sci (2002) 0.84
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res (2006) 0.84
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res (2005) 0.82
Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol (2011) 0.81
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol (2008) 0.81
Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci (2008) 0.80
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs (2010) 0.79
Radioprotective effects of ON 01210.Na upon oral administration. J Radiat Res (2012) 0.78
Characterization of pentamidine excretion in the isolated perfused rat kidney. J Antimicrob Chemother (2003) 0.78
Simulation of the pharmacokinetic profile of methazolamide in blood: effect of erythrocyte carbonic anhydrase binding on drug disposition. Pharm Res (2002) 0.77
Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Biopharm Drug Dispos (2011) 0.77
Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. J Pharmacol Exp Ther (2006) 0.77
Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res (2013) 0.76
Editorial to the themed issue on translational modeling in neuroscience. J Pharmacokinet Pharmacodyn (2013) 0.76
Renal excretion of apricitabine in rats: ex vivo and in vivo studies. Eur J Drug Metab Pharmacokinet (2011) 0.75
Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitro. Int J Pharm (2005) 0.75
In vitro evaluation of the release of albuterol sulfate from polymer gels: effect of fatty acids on drug transport across biological membranes. Drug Dev Ind Pharm (2002) 0.75
Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. J Pharm Sci (2012) 0.75
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol (2008) 0.75
Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Dev Ind Pharm (2010) 0.75
Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. Int J Pharm Compd (2013) 0.75
Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. J Pharm Sci (2008) 0.75
Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure. J Pharm Pharmacol (2013) 0.75